JPH08510720A - 経皮的薬物送り出しのための組成物及び方法 - Google Patents

経皮的薬物送り出しのための組成物及び方法

Info

Publication number
JPH08510720A
JPH08510720A JP6518085A JP51808594A JPH08510720A JP H08510720 A JPH08510720 A JP H08510720A JP 6518085 A JP6518085 A JP 6518085A JP 51808594 A JP51808594 A JP 51808594A JP H08510720 A JPH08510720 A JP H08510720A
Authority
JP
Japan
Prior art keywords
pharmaceutical agent
skin
nucleotide
oligonucleotide
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6518085A
Other languages
English (en)
Japanese (ja)
Inventor
イー. セリック,ハロルド
アール. オールデンバーグ,ケビン
Original Assignee
アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ filed Critical アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ
Publication of JPH08510720A publication Critical patent/JPH08510720A/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Electrotherapy Devices (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP6518085A 1993-01-27 1994-01-26 経皮的薬物送り出しのための組成物及び方法 Pending JPH08510720A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US946393A 1993-01-27 1993-01-27
US7778693A 1993-06-14 1993-06-14
US7729693A 1993-06-14 1993-06-14
US10732993A 1993-08-16 1993-08-16
US08/009,463 1993-08-16
US08/107,329 1993-08-16
US08/077,786 1993-08-16
US08/077,296 1993-08-16
PCT/US1994/000896 WO1994017792A2 (fr) 1993-01-27 1994-01-26 Compositions et procedes d'administration transdermique de medicaments

Publications (1)

Publication Number Publication Date
JPH08510720A true JPH08510720A (ja) 1996-11-12

Family

ID=27485882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6518085A Pending JPH08510720A (ja) 1993-01-27 1994-01-26 経皮的薬物送り出しのための組成物及び方法

Country Status (5)

Country Link
EP (1) EP0683668A4 (fr)
JP (1) JPH08510720A (fr)
AU (1) AU6764794A (fr)
CA (1) CA2153243A1 (fr)
WO (1) WO1994017792A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348449B1 (en) 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
US5942395A (en) * 1997-05-09 1999-08-24 Universite De Montreal Hybrid ribozymes and methods of use
DE19814257A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
BR9816014A (pt) * 1998-09-01 2001-05-08 Idea Ag Transporte eletricamente controlado de penetrantes carregados através de barreiras
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
US6713309B1 (en) 1999-07-30 2004-03-30 Large Scale Proteomics Corporation Microarrays and their manufacture
EP2046954A2 (fr) 2006-07-31 2009-04-15 Curevac GmbH Acide nucléique de formule (i): gixmgn, ou(ii): cixmcn, en particulier en tant qu'agent/adjuvant immunostimulant
US8530436B2 (en) 2007-01-29 2013-09-10 Transderm, Inc. Methods and compositions for transdermal delivery of nucleotides
WO2009030254A1 (fr) 2007-09-04 2009-03-12 Curevac Gmbh Complexes d'arn et de peptides cationiques pour transfection et immunostimulation
DK2176408T5 (en) 2008-01-31 2015-12-14 Curevac Gmbh Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS.
WO2010037408A1 (fr) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprenant un arnm complexé et un arnm nu pour déclencher ou augmenter une réponse immunostimulante chez un mammifère et utilisations de ladite composition
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
KR101761388B1 (ko) 2010-07-30 2017-07-25 큐어백 아게 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체
WO2013113326A1 (fr) 2012-01-31 2013-08-08 Curevac Gmbh Composition pharmaceutique comprenant un complexe support polymère - charge et au moins un antigène de protéine ou de peptide
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
US10369216B2 (en) 2014-04-01 2019-08-06 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
AU609769B2 (en) * 1987-02-10 1991-05-09 Drug Delivery Systems Inc. Electrolytic transdermal delivery of proteins
US5085749A (en) * 1989-03-14 1992-02-04 Massachusetts Institute Of Technology Dynamically controlled membrane
WO1990012022A1 (fr) * 1989-03-31 1990-10-18 University Patents, Inc. Phosphorodithioates de polynucleotides servant d'agents therapeutiques contre des infections retrovirales
US5248670A (en) * 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses

Also Published As

Publication number Publication date
EP0683668A1 (fr) 1995-11-29
WO1994017792A2 (fr) 1994-08-18
AU6764794A (en) 1994-08-29
CA2153243A1 (fr) 1994-08-18
EP0683668A4 (fr) 1997-12-29
WO1994017792A3 (fr) 1994-09-29

Similar Documents

Publication Publication Date Title
JPH08510720A (ja) 経皮的薬物送り出しのための組成物及び方法
Akhtar et al. Interactions of antisense DNa oliginucletide analogs with phospholid membranes (liposomes)
Capaccioli et al. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum
TWI225412B (en) Liposome-entrapped polynucleotide composition and method
US6858226B2 (en) Fusogenic lipids and vesicles
US6287591B1 (en) Charged therapeutic agents encapsulated in lipid particles containing four lipid components
EP1059092B1 (fr) Utilisation de complexes de liposomes cationiques et de polydéoxyribonucléotides comme médicaments
Dujardin et al. Topical gene transfer into rat skin using electroporation
Wilson et al. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles
US20030229040A1 (en) Cationic liposomal delivery system and therapeutic use thereof
EP0983513A1 (fr) Liposomes renfermant des oligonucleotides
KR100723852B1 (ko) 핵산 및 약물 전달용 중성-양이온성 지질
US6559129B1 (en) Cationic liposomal delivery system and therapeutic use thereof
JP2008518998A (ja) 活性物質としてオリゴヌクレオチドを含む医薬組成物におけるまたはそれに関する改善
WO1998013024A2 (fr) Systeme hyaluronique d'administration de medicaments
US7262173B2 (en) Chemosensitizing with liposomes containing oligonucleotides
JP5674923B2 (ja) アンチセンスオリゴヌクレオチドを含む医薬組成物およびそれを使用する方法
Goodchild et al. The clearance and degradation of oligodeoxynucleotides following intravenous injection into rabbits
US6897200B1 (en) Oligonucleotide delivery systems for camptothecins
CN106102773A (zh) 组合物
Nolen III et al. Percutaneous penetration of methyl phosphonate antisense oligonucleotides
KR102306384B1 (ko) 피부 투과성 핵산 복합체를 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 조성물
JP2003523377A (ja) 分子の経皮的又は皮内送達のための方法
AU2001241743A1 (en) Method for transdermal or intradermal delivery of molecules
Preat et al. Topical delivery of nucleic acids in the skin